2. Holick M.F. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr. Opin. Endocrinol. Diabetes 2002;9:87–98.

3. Bennett A.L., Lavie C.J. Vitamin D Metabolism and the Implications for Atherosclerosis. Adv. Exp. Med. Biol. 2017;996:185–192.

4. Pilz S., Trummer C., Pandis M., Schwetz V., Aberer F., Grübler M., Verheyen N., Tomaschitz A., März W. Vitamin D: Current Guidelines and Future Outlook. Anticancer Res. 2018;38(2):1145–115.

5. Bokeriya L.A., Berishvili I.I., Sigayev I.YU. Minimal’no invazivnaya revaskulyarizatsiya miokarda M., 2001.5. Kalinchenko S.YU., Tyuzikov I.A., Gusakova D.A., Vorslov L.O., Tishova YU.A., Grekov Ye.A., Fomin A.M. Vitamin D as a new steroid hormone and its importance for men’s health. Effective pharmacotherapy. Urologiya i nefrologiya. 2015;27:38–34. Russian (Калинченко С.Ю., Тюзиков И.А., Гусакова Д.А., Ворслов Л.О., Тишова Ю.А., Греков Е.А., Фомин А.М. Витамин D как новый стероидный гормон и его значение для мужского здоровья. Эффективная фармакотерапия. Урология и нефрология. 2015;27:38–34).

6. Blomberg J.M., Dissing S. Non-genomic effects of vitamin D in human spermatozoa. Steroids. 2012;77(10):903–909.

7. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F., Lieben L., Mathieu C., Demay M. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocrine Reviews. 2008;29:726–729.

8. Dix C.F., Barcley J.L., Wright O.R.L. The role of vitamin D in adipogenesis. Nutr Rev. 2018;76(1):47–59.

9. Holick M.F. Vitamin D deficiency. New. Eng. J. Med. 2007;357:266–281.

10. Kinuta K., Tanaka H., Moriwake T., Aya K., Kato S., Seino Y. Vitamin D in obesity. Curr. Opin. estrogen biosynthesis of both female and male gonads. Endocrinol. 2000;141:1317–1324.

11. Walsh J.S., Bowles S., Evans A.L. Vitamin D in obesity. Curr. Opin. Endocrinol. Diabetes Obes. 2017;24(6):389–394.

12. Vorslov L.O., Tyuzikov I.A., Kalinchenko S.YU., Gusakova D.A., Tishova YU.A., Puchkova T.V. The quartet of health is a new concept of modern preventive and aesthetic medicine: vitamin D, the possibilities of external and internal application.Kosmetika i meditsina. 2015;4:56–64. Russian (Ворслов Л.О., Тюзиков И.А., Калинченко С.Ю., Гусакова Д.А., Тишова Ю.А., Пучкова Т.В. Квартет здоровья – новая концепция современной профилактической и эстетической медицины: витамин D, возможности наружного и внутреннего применения. Косметика и медицина. 2015;4:56–64).

13. Tyuzikov I.A., Kalinchenko S.Yu., Vorslov L.O., Tishova Yu.A. Vitamin D, men’s health and male reproduction. Andrologiya i genital’naya khirurgiya. 2013;4:36–44. Russian. (Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О., Тишова Ю.А. Витамин D, мужское здоровье и мужская репродукция. Андрология и генитальная хирургия. 2013;4:36–44).

14. Tyuzikov I.A. Hormone D-status in men with andrologic pathology (pilot study). Materialy Mezhdunarodnogo Kongressa «Muzhskoye zdorov’ye». Minsk, 2014. S.90–92. Russian (Тюзиков И.А. Гормон D-статус у мужчин с андрологической патологией (пилотное исследование). Материалы Международного Конгресса «Мужское здоровье». Минск, 2014. С. 90–92).

15. Al-Alyani H., Al-Turki H.A., Al-Essa O.N., Alani F.M., Sadat-Ali M. Vitamin D deficiency in Saudi Arabians: A reality or simply hype: A meta-analysis (2008–2015). J. Family Community Med. 2018;25(1):1–4.

16. Nabi G., Hobani Y., Sarwat M. High prevalence of vitamin D deficiency and cancer in Saudi Arabian populations: Can we hypothesize a link? Med. Hypotheses. 2015;85(2):117–119.

17. Pereira-Santos M., Santos J.Y.G.D., Carvalho G.Q., Santos D.B.D., Oliveira A.M. Epidemiology of vitamin D insufficiency and deficiency in a population in a sunny country: geospatial meta-analysis in Brazil. Crit. Rev. Food Sci. Nutr. 2018. Doi: 10.1080/10408398.2018.1437711.

18. Pleshcheva A.V., Pigarova Ye.A., Dzeranova L.K. Vitamin D and metabolism: facts, myths and prejudices. Ozhireniye i metabolizm. 2012;2:33–42. Russian (Плещева А.В., Пигарова Е.А., Дзеранова Л.К. Витамин D и метаболизм: факты, мифы и предубеждения. Ожирение и метаболизм. 2012;2:33–42).

19. Becker S., Dossus L., Kaaks R. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arq. Bras. Endocrinol. Metabol. 2009;53(2):213–226.

20. Ford J.A., MacLennan G.S., Avenell A., Bolland M., Grey A., Witham M. RECORD Trial Group. Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am. J. Clin. Nutr. 2014;100(3):746–755.

21. Frasca F., Pandini G., Sciacca L., Pezzino V., Squatrito S., Belfiore A., Vigneri R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Am. J. Clin Nutr. 2007;86(3):843–857.

22. Gandini S., Boniol M., Haukka J., Byrnes G., Cox B., Sneyd M.J., Mullie P., Autier P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer. 2011;128(6):1414–24. Doi: 10.1002/ijc.25439.

23. Haghsheno M.A., Mellström D., Behre C.J., Damber J.E., Johansson H., Karlsson M., Lorentzon M., Peeker R., Barret-Connor E., Waern E., Sundh V., Ohlsson C., Hammarsten J. Low 25-OH vitamin D is associated with benign prostatic hyperplasia. J. Urol. 2013;190(2):608–614.

24. Meyer H.E., Robsahm T.E., Bjørge T., Brustad M., Blomhoff R. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr. 2013;97(1):147–154. Doi: 10.3945/ajcn.112.039222

25. Okazaki R. Vitamin D and cancer. Clin. Calcium. 2014;24(8):1193–1199.

26. Pereira-Santos M., Costa P.R., Assis A.M., Santos C.A., Santos D.B. Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes Rev. 2015;16(4):341–349.

27. Santos R.K.F., Brandão-Lima P.N., Tete R.M.D.D., Freire A.R.S, Pires L.V. Vitamin D ratio and glycaemic control in individuals with type 2 diabetes mellitus: A systematic review. Diabetes Metab. Res. Rev. 2017. Doi: 10.1002/dmrr.2969.

28. Tomlinson P.B., Joseph C., Angioi M. Effects of vitamin D supplementation on upper and lower body muscle strength levels in healthy individuals. A systematic review with meta-analysis. J. Sci. Med. Sport. 2014, Aug 11. pii: S1440-2440(14)00163-7. Doi: 10.1016/j.jsams.2014.07.02.

29. Wehr E., Pilz S., Schweighofer N. Giuliani A., Kopera D., Pieber T.R., Obermayer-Pietsch B. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur. J. Endocrinol. 2009;161:575–582. Doi: 10.1530/EJE-09-0432.

30. Xu Y., He B., Pan Y., Deng Q., Sun H., Li R., Gao T., Song G., Wang S. Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Tumour. Biol. 2014;35(5):4153–4169.

31. Xu Y., Shao X., Yao Y. Xu L, Chang L., Jiang Z., Lin Z. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J. Cancer. Res. Clin. Oncol. 2014 May 17. Doi: 10.1007/s00432-014-1706-3.

32. Zittermann A., Prokop S. The role of vitamin D for cardiovascular disease and overall mortality. Adv. Exp. Med. Biol. 2014;810:106–119.

33. Pilz S., Ma¨rz W., Wellnitz B., Seelhorst U., Fahrleitner-Pammer A., Dimai H.P., Boehm B.O., Dobnig H. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. Journal of Clinical Endocrinology and Metabolism. 2008;93:3927–3935.

34. Wehr E., Pilz S., Boehm B.O., Ma¨rz W., Grammer T.B. Obermayer-Pietsch B. Sex steroids and mortality in men referred for coronary angiography. Clinical Endocrinology 2010;73:613–621.

35. Wehr E., Pilz S., Boehm B.O., Ma¨rz W., Grammer T., Obermayer-Pietsch B. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. European Journal of Heart Failure. 2011;13:482–488.

36. Lerchbaum E., Pilz S., Boehm B.O., Grammer T.B., Obermayer-Pietsch B., März W. Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography. Clin Endocrinol (Oxf). 201;77(3):475–83.

37. Chowdhury R., Kunutsor S., Vitezova A., Oliver-Williams C., Chowdhury S., Kiefte-de-Jong J.C., Khan H., Baena C.P., Prabhakaran D., Hoshen M.B., Feldman B.S., Pan A., Johnson L., Crowe F., Hu F.B., Franco O.H. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 2014;348:1903. Doi: 10.1136/bmj.g1903.

38. Ness R.A., Miller D.D., Li W. The role of vitamin D in cancer prevention. Chin. J. Nat. Med. 2015;13(7):481–497.

39. Mordan-McCombs S., Brown T., Wang W.L., Gaupel A.C., Welsh J., Tenniswood M. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. Journal of Steroid Biochemistry and Molecular Biology. 2010;121:368–371.

40. Rojansky N., Brzezinski A., Schenker J.G. Seasonality in human reproduction: an update. Human Reproduction. 1992;7:735–745.

41. Wehr E., Pilz S., Boehm B.O., März W., Obermayer-Pietsch B. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf). 2010;73(2):243–248.

42. Blomberg J.M. Vitamin D metabolism, sex hormones, and male reproductive function. Reproduction. 2012;144(2):135–152.

43. Lee D.M., Tajar A., Pye S.R., Boonen S., Vanderschueren D., Bouillon R., O’Neill T.W., Bartfai G., Casanueva F.F., Finn J.D., Forti G., Giwercman A., Han T.S., Huhtaniemi I.T., Kula K., Lean M.E., Pendleton N., Punab M., Wu F.C. Association of hypogonadism with vitamin D status: the European Male Ageing Study. European Journal of Endocrinology 2012;166:77–85.

44. Jorde R., Grimnes G., Hutchinson M.S., Kjærgaard M., Kamycheva E., Svartberg J. Supplementation with vitamin D does not increase serum testosterone levels in healthy males. Horm Metab Res. 2013;45(9):675–681.

45. Nimptsch K., Platz E.A., Willett W.C., Giovannucci E. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin. Endocrinol. (Oxf). 2012;77(1):106–112.

46. Pilz S., Frisch S., Koertke H., Kuhn J., Dreier J., Obermayer-Pietsch B., Wehr E., Zittermann A. Effect of vitamin D supplementation on testosterone levels in men. Hormone and Metabolic Research. 2011;43:223–225.

47. Boucher B.J. Is vitamin D status relevant to metabolic syndrome? Dermatoendocrinol. 2012;4(2):212–24.

48. Challa A.S., Makariou S.E., Siomou E.C. The relation of vitamin D status with metabolic syndrome in childhood and adolescence: an update. J. Pediatr. Endocrinol. Metab. 2015;28(11–12):1235–1245.

49. Florentin M., Elisaf M.S., Mikhailidis D.P., Liberopoulos E.N. Vitamin D and metabolic syndrome: is there a link? Curr. Pharm Des. 2010;16(30):3417–3434.

50. Khosravi-Boroujeni H., Ahmed F., Sarrafzadegan N. Is the Association between Vitamin D and Metabolic Syndrome Independent of Other Micronutrients. Int. J. Vitam. Nutr. Res. 2016;20:1–16.

51. Muldowney S., Kiely M. Vitamin D and cardiometabolic health: a review of the evidence. Nutr. Res. Rev. 2011;24(1):1–20.

52. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F. Decreased bioavailability of vitamin D in obesity. American Journal of Clinical Nutrition. 2000;72:690–693.

53. Compston J.E., Vedi S., Ledger J.E., Webb A., Gazet J.C., Pilkington T.R. Vitamin D status and bone histomorphometry in gross obesity. American Journal of Clinical Nutrition. 1981;34:2359–2363.

54. Hahn S., Haselhorst U., Tan S., Quadbeck B., Schmidt M., Roesler S., Kimmig R., Mann K., Janssen O.E. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology and Diabetes. 2006;114:577–583.

55. Kamycheva E., Joakimsen R.M., Jorde R. Intakes of calcium and vitamin D predict body mass index in the population of Northern Norway. Journal of Nutrition. 2003;133:102–106.

56. Bellastella G., Maiorino M.I., Olita L., Capuano A., Rafaniello C., Giugliano D., Esposito K. Vitamin D deficiency in type 2 diabetic patients with hypogonadism. J. Sex Med. 2014;11(2):536–542.

57. Khan H., Kunutsor S., Franco O.H., Chowdhury R. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc. Nutr Soc. 2013;72(1):89–97.

58. Li H.W., Brereton R.E., Anderson R.A., Wallace A.M., Ho C.K. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism. 2011;60:1475–1481.

59. Ngo D.T., Chan W.P., Rajendran S., Heresztyn .T, Amarasekera A.,Sverdlov A.L., O’Loughlin P.D., Morris H.A., Chirkov Y.Y., Norman R..J, Horowitz J.D. Determinants of insulin responsiveness in young women: impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric. Oxide. 2011;25:326–330.

60. Maestro B., Molero S., Bajo S., Da´vila N., Calle C. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochemistry and Function. 2002;20:227–232.

61. Maestro B., Da´vila N., Carranza M.C.,Calle C. Identification of a vitamin D response element in the human insulin receptor gene promoter. Journal of Steroid Biochemistry and Molecular Biology. 2003;84:223–230.

62. Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism. 2007;92:2017–2029.

63. Milner R.D., Hales C.N. The role of calcium and magnesium in insulin secretion from rabbit pancreas studied in vitro. Diabetologia. 1967;3:47–49.

64. Bikle D. Nonclassic actions of vitamin D. Journal of Clinical Endocrinology and Metabolism. 2009; 94:26–34.

65. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–2180.

66. Hammer Y., Soudry A., Levi A., Talmor-Barkan Y., Leshem-Lev D., Singer J., Kornowski R., Lev E.I. Effect of vitamin D on endothelial progenitor cells function. PLoS One. 2017;17;12(5):e0178057.

67. Manouchehri N., Vakil-Asadollahi M., Zandifar A., Rasmani F., Saadatnia M. Vitamin D Status in Small Vessel and Large Vessel Ischemic Stroke Patients: A Case-control Study. Adv. Biomed Res. 2017;30;6:146.

68. Pál É., Hadjadj L., Fontányi Z., Monori-Kiss A., Mezei Z., Lippai N., Magyar A., Heinzlmann A., Karvaly G., Monos E., Nádasy G., Benyó Z., Várbíró S. Vitamin D deficiency causes inward hypertrophic remodeling and alters vascular reactivity of rat cerebral arterioles. PLoS One. 2018; 6:13(2):e0192480.

69. Alyami A.M., Lam V., Soares M.J., Zhao Y., Sherriff J.L., Mamo J.C., James A.P., Coombes F. The Association of Vitamin D Status with Dyslipidaemia and Biomarkers of Endothelial Cell Activation in Older Australians. Nutrients. 2016;28:8(8). pii: E457. Doi: 10.3390/nu8080457.

70. Hou Y.C., Liu W.C., Zheng C.M., Zheng J.Q., Yen T.H., Lu K.C. Role of Vitamin D in Uremic Vascular Calcification. Biomed .Res Int. 2017;2017:2803579.

71. Kumar V., Yadav A.K., Lal A., Kumar V., Singhal M., Billot L., Gupta K.L., Banerjee D., Jha V. A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD. J. Am. Soc. Nephrol. 2017;28(10):3100–3108.

72. Agbalalah T., Hughes S.F., Freeborn E.J., Mushtaq S. Impact of vitamin D supplementation on endothelial and inflammatory markers in adults: A systematic review. J. Steroid. Biochem. Mol. Biol. 2017;173:292–300.

73. Manchanda P.K., Konwar R., Nayak V.L., Singh V., Bid H.K. Association of genetic variants of the vitamin D receptor (VDR) gene (Fok-I, Taq-I and Bsm-I) with susceptibility of benign prostatic hyperplasia in a North Indian population. Asian. Pac. J. Cancer Prev. 2010;11(4):1005–1008.

74. Ruan L., Zhong W.D., Li Z.M., Hua X. Relationship between vitamin D receptor gene Fok I polymorphisms and benign prostatic hyperplasia complicated by histological prostatitis Zhonghua Nan. Ke Xue. 2011;17(10):880–883.

75. Pitman M.S., Cheetham P.J., Hruby G.W., Katz A.E. Vitamin D deficiency in the urological population: a single center analysis. J. Urol. 2011;186(4):1395–1399.

76. Wieczorek K., Braczkowski R.S., Skrzypek M., Stryjewski P.J., Kuczaj A., Al-Srory G. The comparison between vitamin d concentration in upper silesia patients with prostate cancer and with benign prostatic hyperplasia. J. Biol. Regul. Homeost Agents. 2015;29(1):207–11.

77. Murphy A.B., Nyame Y., Martin I.K., Catalona W.J., Hollowell C.M, Nadler R.B., Kozlowski J.M., Perry K.T., Kajdacsy-Balla A., Kittles R. Vitamin D deficiency predicts prostate biopsy outcomes. Clin. Cancer Res. 2014;20(9):2289–2299.

78. Grant W.B. Vitamin d status: ready for guiding prostate cancer diagnosis and treatment? Clin. Cancer Res. 2014;20(9):2241–2243.

79. Tyuzikov I.A., Kalinchenko S.YU., Vorslov L.O., Tishova YU.A. Vitamin D, men’s health and the prostate gland (a review of the literature). Andrologiya i genital’naya khirurgiya. 2014. №3. S. 26–32. Russian (Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О., Тишова Ю.А. Витамин D, мужское здоровье и предстательная железа (обзор литературы). Андрология и генитальная хирургия. 2014. № 3. С. 26–32).

80. Manchanda P.K., Kibler A.J., Zhang M., Ravi J., Bid H.K. Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia. Indian. J. Urol. 2012;28(4):377–381.

81. Sampson N., Madersbacher S., Berger P. Pathophysiology and therapy of benign prostatic hyperplasia. Wien. Klin. Wochenschr. 2008;120(13–14):390–401.

82. Galunska B., Gerova D., Kosev P., Anakievski D., Hinev A. Serum 25-hydroxy vitamin D levels in Bulgarian patients with prostate cancer: a pilot study. Clin Lab. 2015;61(3–4):329–335.

83. Caretta N., Vigili de Kreutzenberg S., Valente U., Guarneri G., Pizzol D., Ferlin A., Avogaro A., Foresta C. Hypovitaminosis D is associated with lower urinary tract symptoms and benign prostate hyperplasia in type 2 diabetes. Andrology. 2015;3(6):1062–1067.

84. Elshazly M.A., Sultan M.F., Aboutaleb H.A., Salem S.M., Aziz M.S., Abd Elbaky T.M., Elsherif E.A., Gawish M.M., Alajrawi F.T., Elgadi F.A.A., Thaher A.H., Shebl M.A., Allam A.M., Kehinde E. Vitamin D deficiency and lower urinary tract symptoms in males above 50 years of age. Urol. Ann. 2017;9(2):170–173.

85. Park S.G., Yeo J.K., Cho D.Y., Park M.G. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. Aging Male. 2017;17:1–5.

86. Zhang W., Zheng X., Wang Y., Xiao H. Vitamin D Deficiency as a Potential Marker of Benign Prostatic Hyperplasia. Urology. 2016;97:212–218.

87. Cartwright R., Mangera A., Tikkinen K.A., Rajan P., Pesonen J., Kirby A.C., Thiagamoorthy G., Ambrose C., Gonzalez-Maffe J., Bennett P.R., Palmer T., Walley A., Järvelin M.R., Khullar V., Chapple C. Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men. Eur. Urol. 2014;66(4):752–768.

88. Gsur A., Madersbacher S., Haidinger G., Schatzl G., Marberger M., Vutuc C., Micksche M. Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate. 2002;51(1):30–4.

89. Habuchi T., Suzuki T., Sasaki R., Wang L., Sato K., Satoh S., Akao T., Tsuchiya N., Shimoda N., Wada Y., Koizumi A., Chihara J., Ogawa O., Kato T. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000;60(2):305–308.

90. Kivineva M., Bläuer M., Syvälä H., Tammela T., Tuohimaa P. Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J. Steroid. Biochem. Mol. Biol. 1998;66(3):121–127.

91. Zeng X.T., Yao Q.S., Weng H., Li S., Huang J.Y., Wang X.H. Meta-analysis of vitamin D receptor gene polymorphisms and benign prostatic hyperplasia risk. Mol. Biol .Rep. 2014;41(10):6713–6717.

92. Chughtai B., Lee R., Te A., Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev. Urol. 2011;13(3):147–150.

93. Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 2008;4(8):404–412.

94. Fibbi B., Penna G., Morelli A., Adorini L., Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int. J. Androl. 2010;33(3):475–488.

95. Hamid A.R., Umbas R., Mochtar C.A. Recent role of inflammation in prostate diseases: chemoprevention development opportunity. Acta. Med. Indones. 2011;43(1):59–65.

96. Motrich R.D., van Etten E., Depovere J., Riera C.M., Rivero V.E., Mathieu C. Impact of vitamin D receptor activity on experimental autoimmune prostatitis. J. Autoimmun. 2009;32(2):140–148.

97. Ghosn J., Viard J.P. Vitamin D and infectious diseases. Presse. Med. 2013;42(10):1371–1376.

98. Hewison M. Antibacterial effects of vitamin D. Nat. Rev. Endocrinol. 2011;7(6):337–345.

99. Penna G., Fibbi B., Amuchastegui S., Corsiero E., Laverny G., Silvestrini E., Chavalmane A., Morelli A., Sarchielli E., Vannelli G.B., Gacci M., Colli E., Maggi M., Adorini L. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009;69(5):480–493.

100. Espinosa G., Esposito R., Kazzazi A., Djavan B. Vitamin D and benign prostatic hyperplasia – a review. Can. J. Urol. 2013;20(4):6820–6825.

101. Comeglio P., Chavalmane A.K., Fibbi B., Filippi S., Marchetta M., Marini M., Morelli A., Penna G., Vignozzi L., Vannelli G.B., Adorini L., Maggi M. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. J. Endocrinol. Invest. 2010;33(10):730–738.

102. Adorini L., Penna G., Fibbi B., Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann. N. Y. Acad. Sci. 2010;1193:146–152.

103. Crescioli C., Morelli A., Adorini L., Ferruzzi P., Luconi M., Vannelli G.B., Marini M., Gelmini S., Fibbi B, Donati S, Villari D, Forti G, Colli E, Andersson KE, Maggi M. Human bladder as a novel target for vitamin D receptor ligands. J. Clin. Endocrinol. Metab. 2005;90(2):962–972.

104. Mullan R.J., Bergstralh E.J., Farmer S.A., Jacobson D.J., Hebbring S.J., Cunningham J.M., Thibodeau S.N., Lieber M.M., Jacobsen S.J., Roberts R.O. Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men. Urology. 2006;67(2):300–3005.

105. Tiwari A. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. IDrugs. 2009;12(6):381–393.

106. Annweiler C., Henni S., Walrand S., Montero-Odasso M., Duque G., Duval G.T. Vitamin D and walking speed in older adults: Systematic review and meta-analysis. Maturitas. 2017;106:8–25.

107. Bruyère O., Cavalier E., Reginster J.Y. Vitamin D and osteosarcopenia: an update from epidemiological studies. Curr. Opin. Clin. Nutr. Metab. Care. 2017;20(6):498–503.

108. Dawson-Hughes B. Vitamin D and muscle function. J. Steroid Biochem. Mol. Biol. 2017;173:313–316.

109. Kaneko I., Miyamoto K.I., Nikawa T. Update on recent progress in vitamin D research. Vitamin D and muscle tissues. Clin. Calcium. 2017;27(11):1571–1578.

110. Yalçınkaya S., Eren E., Eroglu M., Aydin O., Yilmaz N. Deficiency of vitamin D and elevated aldosterone in prostate hyperplasia. Adv. Clin. Exp. Med. 2014;23(3):441–446.